Apologies hazl...
Just looked at the date on the web page instead of when the article was published...
Amazing that this article was first piblished in 2019, and now 5 years later it still hasn't been rolled out in the NHS.. |
People are not having babies anymore what use is the baby hearing kit if people ain't making babies |
EDIT.
Are you sure that was today?
Looks like a very old article by the date, however valid.
Disappointing you got me going then. |
In the Daily MAil today
Monday will be interesting... |
2,000,000 ! Another director buy perhaps. |
A nice 2,000,00 buy at close by the looks of it.
8-) |
Gino Miele, CEO of genedrive plc, said: "We are delighted with the clinical performance of our CYP2C19 ID Kit reported in this publication. With recommendation by NICE as the PoC test of choice for CYP2C19 genotyping in IS/TIA in NHS England, dominant health economic modelling by NICE, positive value assessment by the Scottish Health Technology Group, together with this study evidencing superior performance compared to laboratory testing and by extrapolation our nearest competitor product, we are well positioned to capitalise on the emerging clinical pharmacogenetics area of point of care CYP2C19 genotyped-guided clopidogrel treatment both domestically and internationally, ultimately enabling better patient outcomes, improving equitable access to healthcare and positively impacting healthcare financial burdens."
For further details please contact: |
Agree far and away a good announcement.
8-) |
Suitors interest levels are increasing.Great RNS update.Immensely upbeat 2025 for GDR and their investors. |
No 13 on the leader board.
If this was a normal day and not such thin trade I would have expected to see this a lot higher. |
PS: there's plenty of evidence of placings at a premium for late stage trial companies with horizon hockey stick revenue. OBI one such company. |
Thanks Bones Not sure what a "ramper" is really. I bought some when they were derisked back at 1.5p, again in at just above the current price. The key word is "derisked". The company will grow from here, that's not to say we won't get a discounted fundraise because that's always a risk. However even by your figures that would be within the current trading range. I'd hazard my own "guess" here that the price will be much higher by the time they need more money.Out of interest, why would people need to put up an argument against you? You aren't exactly Soros, maybe you are a clinical expert? Either way you are just a chancet like the rest of us, so maybe chill out a bit eh? |
It does make you wonder how many institutions might see this reference in the medical journal. |
Note 'clinically superior'. |
Naysayers haven't a leg to stand on with the feat this company have pulled off!
Thanks to John McDermott are definitely due, for his dedication in taking this 'clinically,' under his wing, if that's the right word and his enthusiasm!
IMO |
I suspect that I ought not to post snippets of it, because of certain rights, but it's there for people to see.
Technical of course, but so rewarding to see in print! |
What an accolade! |
Lmao 3 down ticks but not a single valid or solid argument against my points . Says it all really .that's because the facts are there and what the rampers would like you to believe is all hot air really . Let's see what happens shell we |
 Just remember the last time they raised the share price was 6p prior to the announcement and they raised 6m at 1.5p . The share price this time is likely to be between 1.7 and 2.3p so where will it be after they raise another similar amount ?
They need money soon look at the results and cash burn and despite what the rampers say a fund raise is the most likely way it will happen by some margin ..
Wait until they raise before investing here long term imo . I said the same last time and it happened despite the likes of hazel and others saying it wouldn't . Now I am predicting the same again.Be warned .
Burning through 500k a month I suggest people look at the last known cash position and work it out for themselves . .
I'll predict a raise of 6m at 1p or under,possibly as low as 0.5p , and that will only last another year at best
The tech works it's great but that doesn't make it a profitable business im afraid and cash in the bank is the problem with very slowly increasing revenues
From results
Cash at bank of £5.2m at 30 June 2024 (2023: £2.6m) and debt free
So 10 months cash meaning a fund raise early next year probably march . Watch this fall as it approaches imo |
results look excellent
and I do have some skin in the game .. not just bones |
Morning with bod buying and more good news others will notice this!! |
Thanks for the prediction Bones. Highly inaccurate I expect, but thanks anyway.GDRs tests shown to be more cost effective, accurate, and picked up on some missed in the alternative setting. That'll do for me. Further published and peer reviewed evidence of the benefits of using GDRs product here.At a smidging over 2p, not a lot not to like here. I expect any fundraise will follow significant orders, and be at a higher price than this. |
Good results but we knew this already . Unfortunately it doesn't change the fact they will need funding soon and revenue is not increasing fast enough to mean that at least one maybe two or three are needed .these fund raises will almost certainly mean more dilution and a lower share price is coming and why there are a lot of short term traders here . The share price will start to drop steadily when they approach the city imo |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
